RHBDD1 (rhomboid domain containing 1) is an intramembrane serine protease that functions as an oncogene in multiple cancer types. The protein promotes tumor progression through activation of key signaling pathways, particularly the Wnt/β-catenin pathway 1 2. In pancreatic adenocarcinoma, RHBDD1 enhances cell proliferation and metastasis via the AKT/GSK-3β/β-catenin pathway, with high expression correlating with poor patient prognosis 3. Similarly, in breast cancer, RHBDD1 promotes progression by regulating p-Akt and CDK2 protein levels, facilitating cell cycle progression and G1/S transition 4. RHBDD1 demonstrates protumorigenic effects across colorectal cancer by promoting metastasis through Wnt signaling and downstream target ZEB1 2, and in gastric cancer by enhancing growth and stemness characteristics 1. The protein is consistently overexpressed in various malignancies including chr2 myeloid leukemia 5 and shows strong correlation with tumor-infiltrating immune cells, suggesting immunological significance 6. Therapeutic targeting of RHBDD1 through knockdown strategies consistently produces anticancer effects, including growth inhibition, cell cycle arrest, and apoptosis induction across multiple cancer models 3 7. These findings establish RHBDD1 as a potential biomarker and therapeutic target in oncology.